{"name":"TG Therapeutics","slug":"tg-therapeutics","ticker":"TGTX","exchange":"NASDAQ","domain":"tgtherapeutics.com","description":"TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Phar","hq":"New York, NY","founded":0,"employees":"399","ceo":"Michael S. Weiss","sector":"Hematology / Neurology","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":41.36,"stockChange":-1.29,"stockChangePercent":-3.02,"marketCap":"$6.3B","metrics":{"revenue":700348992,"revenueGrowth":69.6,"grossMargin":83.1,"rdSpend":160215000,"netIncome":447179000,"cash":514430016,"dividendYield":0,"peRatio":14.5,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-12-01","label":"BRIUMVI Phase 3 readout (Relapsing Multiple Sclerosis)","drug":"BRIUMVI","drugSlug":"ublituximab-xiiy","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-10-01","label":"BRIUMVI Phase 3 readout (Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis)","drug":"BRIUMVI","drugSlug":"ublituximab-xiiy","type":"phase3_readout","sentiment":"neutral"},{"date":"2033-06-30","label":"BRIUMVI Phase 2 readout (Relapsing Multiple Sclerosis)","drug":"BRIUMVI","drugSlug":"ublituximab-xiiy","type":"phase3_readout","sentiment":"neutral"},{"date":"2034-06-01","label":"Umbralisib patent cliff ($1.2B at risk)","drug":"Umbralisib","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BRIUMVI","genericName":"UBLITUXIMAB-XIIY","slug":"ublituximab-xiiy","indication":"Relapsing forms of multiple sclerosis","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"TG-1501","genericName":"TG-1501","slug":"tg-1501","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"BRIUMVI","genericName":"UBLITUXIMAB-XIIY","slug":"ublituximab-xiiy","phase":"marketed","mechanism":"B-lymphocyte antigen CD20","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"TG-1501","genericName":"TG-1501","slug":"tg-1501","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-22","type":"regulatory","headline":"TG Therapeutics Announces FDA Approval of Umbralisib for the Treatment of Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL)","summary":"The FDA has approved Umbralisib for the treatment of adult patients with relapsed or refractory MZL and FL.","drugName":"Umbralisib","sentiment":"positive"},{"date":"2022-08-09","type":"earnings","headline":"TG Therapeutics Reports Second Quarter 2022 Financial Results","summary":"TG Therapeutics reported its second quarter 2022 financial results, with revenue of $13.4 million and a net loss of $34.1 million.","drugName":"","sentiment":"neutral"},{"date":"2022-05-23","type":"deal","headline":"TG Therapeutics Announces Collaboration with the National Comprehensive Cancer Network (NCCN) to Develop Clinical Practice Guidelines for the Treatment of Marginal Zone Lymphoma (MZL)","summary":"TG Therapeutics has announced a collaboration with the NCCN to develop clinical practice guidelines for the treatment of MZL.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNU1l4NTNibzVoWk1GRTFfQklnUllielBYeDRaRThhU0R4dzl5T3l5OWZJQUZEcGZIZV8wY0RLUUZYVlBmWU5IYWxKdjA4Ukc0S1JmdUFkLWtGZldBQnBiV2ZYdEpzYm9JaDRtZGZGVWNudkdZeFhnWkFySlhSb0V5cE9KT0dGTTQ2bWJsRExqOExmMDNGUkh2Mk16TjYzQQ?oc=5","date":"2026-02-27","type":"pipeline","source":"TradingView","summary":"TG THERAPEUTICS, INC. SEC 10-K Report - TradingView","headline":"TG THERAPEUTICS, INC. SEC 10-K Report","sentiment":"neutral"},{"date":"2026-02-27","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNU0IwQ251TXpreXFFMTRrT1hleFpfNF9hYVBpYkdLZzhVX0VoRHp1YXdfanVLX3E0Ym9YRVVFLU8zeWVxU1hQallhMnhyWm82WnZibkZGbGdpc002dU1DUlZvYzFGWVlicVRXVGpNLXFNYThnYnJnVGpWcmEzbm9lYkNKSDA5MW0zaVotbTZJLUVVWGt0UHNKN0RUckd4Q29sWWNJMWpmd1NFTTVjVndV?oc=5","date":"2026-02-23","type":"earnings","source":"Finviz","summary":"TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release - Finviz","headline":"TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release","sentiment":"neutral"},{"date":"2026-01-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPUV9IVXotb01tZzcyaUVRWTI4Z3MyVVFXeXhPR2xldUtzRDFSTWRhU0t6MEZhOUpPRHIzejVQaUtPYl9aelhhVEozNHJpYkhQQlRvVlVIZUJfcG02ekxBVkxYX1JQdDF4WE1yMU5aM082emNuSzNyOWpkSVdjZkhxOVhVbVVVYXBUS0FMdzZQYWZRaTRJWi1CaDYyY2Q?oc=5","date":"2026-01-10","type":"pipeline","source":"TechStock²","summary":"TG Therapeutics stock slid nearly 7% Friday — what to watch next week for TGTX - TechStock²","headline":"TG Therapeutics stock slid nearly 7% Friday — what to watch next week for TGTX - TechStock²","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPRHIzY2hPZl9WMTVRTEw4NEFOdHh1a3V5N1I3WkU5OGtJdlhlN3paZmJaQS1aY2lEVkNuSjJxLWtZdHVoX1NzOFdaRFEyMkVSTTBnaUxpa1FvVHVkNEttZDJFQ2c3Z0lJendIaDViV3ZnZnhZRzlISGw5Z2pUVnNpZ2RzMWstOWlLQnFhdy1HMEtDN01C?oc=5","date":"2025-12-30","type":"pipeline","source":"Seeking Alpha","summary":"TG Therapeutics: What Wall Street Isn't Telling You (NASDAQ:TGTX) - Seeking Alpha","headline":"TG Therapeutics: What Wall Street Isn't Telling You (NASDAQ:TGTX)","sentiment":"neutral"},{"date":"2025-11-05","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOTnZSZUR1N1psS0hlTnFsZ1IxMFkyTEMwNnpNMEM3MS1TbHNTd3Z2Y0FkWFktSFk1aXhTaGVKTngyTFQ4ZFNxVGJLNE5GbjR2bWhFYVhDaHJTQVQybm5pdVJaNnQ0NWxMM0k0RWpub0tZWkdkOUd1Y01qWHJyVk5saUQ1djQ?oc=5","date":"2025-11-04","type":"earnings","source":"Yahoo Finance","summary":"TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised - Yahoo Finance","headline":"TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised","sentiment":"neutral"},{"date":"2025-11-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-23","type":"pipeline","source":"simplywall.st","summary":"TG Therapeutics (NASDAQ:TGTX) Takes On Some Risk With Its Use Of Debt - simplywall.st","headline":"TG Therapeutics (NASDAQ:TGTX) Takes On Some Risk With Its Use Of Debt","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-30","type":"pipeline","source":"simplywall.st","summary":"What TG Therapeutics, Inc.'s (NASDAQ:TGTX) 26% Share Price Gain Is Not Telling You - simplywall.st","headline":"What TG Therapeutics, Inc.'s (NASDAQ:TGTX) 26% Share Price Gain Is Not Telling You","sentiment":"neutral"},{"date":"2025-08-08","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-08-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[{"drugName":"Umbralisib","drugSlug":"umbralisib","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":2,"phaseCounts":{"marketed":1,"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Roche Holding","Bristol-Myers Squibb"],"therapeuticFocus":["Hematology","Neurology"],"financials":{"source":"sec_edgar+yahoo","revenue":2785000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":2785000,"period":"2022-12-31"},{"value":6689000,"period":"2021-12-31"},{"value":6689000,"period":"2021-12-31"},{"value":152000,"period":"2020-12-31"},{"value":152000,"period":"2020-12-31"}],"grossProfit":515573000,"grossProfitHistory":[{"period":"2025-12-31","value":515573000},{"period":"2024-12-31","value":290518000},{"period":"2023-12-31","value":219531000},{"period":"2022-12-31","value":2520000}],"rdSpend":160215000,"rdSpendHistory":[{"period":"2025-12-31","value":160215000},{"period":"2024-12-31","value":94291000},{"period":"2023-12-31","value":76192000},{"period":"2022-12-31","value":125352000}],"sgaSpend":232034000,"operatingIncome":123324000,"operatingIncomeHistory":[{"period":"2025-12-31","value":123324000},{"period":"2024-12-31","value":41929000},{"period":"2023-12-31","value":20633000},{"period":"2022-12-31","value":-218316000}],"netIncome":447179000,"netIncomeHistory":[{"period":"2025-12-31","value":447179000},{"period":"2024-12-31","value":23383000},{"period":"2023-12-31","value":12672000},{"period":"2022-12-31","value":-223812000}],"eps":2.77,"epsHistory":[{"period":"2025-12-31","value":2.77},{"period":"2024-12-31","value":0.15},{"period":"2023-12-31","value":0.09},{"period":"2022-12-31","value":-1.46}],"cash":79148000,"cashHistory":[{"period":"2025-12-31","value":79148000},{"period":"2024-12-31","value":179894000},{"period":"2023-12-31","value":92933000},{"period":"2022-12-31","value":102304000}],"totalAssets":1063253000,"totalLiabilities":415233000,"totalDebt":253710000,"equity":648020000,"operatingCashflow":-24772000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-24772000},{"period":"2024-12-31","value":-40517000},{"period":"2023-12-31","value":-31413000},{"period":"2022-12-31","value":-176170000}],"capex":-214000,"capexHistory":[{"period":"2025-12-31","value":-214000},{"period":"2024-12-31","value":-45000},{"period":"2022-12-31","value":-14000},{"period":"2021-12-31","value":-401000}],"freeCashflow":-24986000,"dividendsPaid":0,"buybacks":-91240000,"employees":399,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":62745000,"ebit":51626000,"ebitda":51693000,"period":"2025-12-31","revenue":192574000,"epsBasic":0.16,"netIncome":23037000,"rdExpense":41193000,"epsDiluted":0.14,"grossProfit":154432000,"operatingIncome":50494000},{"sga":63373000,"ebit":32630000,"ebitda":32692000,"period":"2025-09-30","revenue":161709000,"epsBasic":2.69,"netIncome":390895000,"rdExpense":40878000,"epsDiluted":2.43,"grossProfit":133616000,"operatingIncome":29365000},{"sga":55585000,"ebit":37636000,"ebitda":37695000,"period":"2025-06-30","revenue":141148000,"epsBasic":0.19,"netIncome":28187000,"rdExpense":31782000,"epsDiluted":0.17,"grossProfit":122210000,"operatingIncome":34843000},{"sga":50331000,"ebit":12225000,"ebitda":12281000,"period":"2025-03-31","revenue":120856000,"epsBasic":0.03,"netIncome":5060000,"rdExpense":46362000,"epsDiluted":0.03,"grossProfit":105315000,"operatingIncome":8622000},{"sga":38963000,"ebit":32514000,"ebitda":32576000,"period":"2024-12-31","revenue":108185000,"epsBasic":0.16,"netIncome":23331000,"rdExpense":23874000,"epsDiluted":0.15,"grossProfit":92786000,"operatingIncome":29949000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":41.36,"previousClose":42.65,"fiftyTwoWeekHigh":44.65,"fiftyTwoWeekLow":25.28,"fiftyTwoWeekRange":"25.28 - 44.65","fiftyDayAverage":33.88,"twoHundredDayAverage":32.01,"beta":1.68,"enterpriseValue":6283613184,"forwardPE":15.2,"priceToBook":9.15,"priceToSales":9.04,"enterpriseToRevenue":8.97,"enterpriseToEbitda":42.01,"pegRatio":0,"ebitda":149580000,"ebitdaMargin":21.4,"freeCashflow":-30164876,"operatingCashflow":-13951000,"totalDebt":753556992,"debtToEquity":129.2,"currentRatio":5.81,"returnOnAssets":8.6,"returnOnEquity":112.6,"analystRating":"1.7 - Buy","recommendationKey":"buy","numberOfAnalysts":7,"targetMeanPrice":48.14,"targetHighPrice":70,"targetLowPrice":17,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":7.5,"institutionHeldPercent":70.2,"sharesOutstanding":153083580,"floatShares":135104544,"sharesShort":27026022,"shortRatio":14.9,"shortPercentOfFloat":17.6,"epsTrailing":2.86,"epsForward":2.73,"revenuePerShare":4.87,"bookValue":4.52,"officers":[{"age":59,"name":"Mr. Michael S. Weiss Esq., J.D.","title":"Chairman, CEO & President"},{"age":43,"name":"Mr. Sean A. Power CPA","title":"CFO, Corporate Secretary & Treasurer"},{"age":null,"name":"Ms. Jenna  Bosco","title":"Senior Vice President of Corporate Communications"},{"age":null,"name":"Mr. Adam  Waldman","title":"Chief Commercialization Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.tgtherapeutics.com","phone":"212 554 4484"}}